GLOBAL PHASE II STUDY OF RISOVALISIB, A SELECTIVE PI3Kα INHIBITOR, AS MONOTHERAPY IN PATIENTS WITH RECURRENT/PERSISTENT OVARIAN CLEAR CELL CARCINOMA HARBORING PIK3CA HOTSPOT MUTATIONS

作者：Xiaohua Wu, Kan Yonemori, Kaoru Niimi, Satoshi Nakagawa, Jiajia Li, Jihong Liu, Kosuke Yoshihara, Shogo Shigeta, Jianqing Zhu, Hui Qiu, Jie Tang, Hidemichi Watari, Tatsuyuki Chiyoda, Shoji Nagao, Liang ZhiQing, Yuanguang Meng, Huimei Zhou, R. An, Aikou Okamoto, Shin Nishio, Kazuhiro Takehara, Junzo Hamanishi, Shuzhong Yao, Fengxia Xue, Ge Lou, Hongming Pan, Wenjun Cheng, Rutie Yin, Wei Duan, Muneaki Shimada · 发表于：International Journal of Gynecological Cancer · 年份：2025 · DOI：10.1016/j.ijgc.2025.102737 · 被引用次数：5 · 研究领域：Cell death mechanisms and regulation、PI3K/AKT/mTOR signaling in cancer、NF-κB Signaling Pathways